A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
Completed · Phase 2 · NCT05730725
Conditions: Psoriasis
At a glance
- Research payments reported, 2025
- $78,651
- U.S. investigators named
- 4
- Sites paid
- 3
- Planned or actual enrollment
- 109
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- BMS-986322 (drug), Placebo (other)
- Dates
- Started 2023-04-03; completion 2024-08-06
- Results posted
- Yes
The purpose of this study is to evaluate clinical effectiveness and safety of BMS-986322 in participants with moderate-to-severe psoriasis.
From ClinicalTrials.gov, last updated 2025-11-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $78,651 in research payments for this study in 2025 (4 payments).
Products named: Augtyro
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Steven Y. Liu, M.D. Hematology & Oncology · Anchorage, AK
- Gerald S. Falchook, MD Medical Oncology · Denver, CO
- Melissa L. Johnson, MD Medical Oncology · Nashville, TN
- Harpaul S. Gill, MD Neurology · Cypress, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sarah Cannon Research Institute, Llc $47,000
- Alaska Oncology and Hematology, Llc $26,140
- Northside Hospital Gwinnett $5,511
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.